Image via Wikipedia
Ever since human induced pluripotent stem cells were first derived in 2007, scientists have wondered whether they were functionally equivalent to embryonic stem cells, which are sourced in early stage embryos.
Both cell types have the ability to differentiate into any cell in the body, but their origins — in embryonic and adult tissue — suggest that they are not identical.
Although both cell types have great potential in basic biological research and in cell- and tissue-replacement therapy, the newer form, called IPS cells, have two advantages. They face less ethical constraint, as they do not require embryos.
Japanese researchers have been able to improve the symptoms of Parkinson’s disease in monkeys by transplanting nerve cells derived from embryonic stem cells into their brains, the team has announced.
The finding is the world’s first reported success of its kind with a primate, according to the research team led by Associate Prof. Jun Takahashi of Kyoto University‘s Institute for Frontier Medical Sciences. It has been released in the online edition of U.S. journal Stem Cells.
After the transplant, the monkeys, which had been almost unable to move, showed improvements in their symptoms to the point where they became able to
A year after President Barack Obama issued a landmark executive order to remove eight years of limitations on U.S. federal funding of stem cell research, the WiCell Research Institute has expanded the number of cell lines available through its WISC Bank (Wisconsin International Stem Cell) to 33.
WiCell, host of the former National Stem Cell Bank (NSCB) for five years under a contract from the National Institutes of Health (NIH), has transitioned the distribution of all of the 20 human embryonic stem cell (hESC) lines formerly available through the NSCB to its own stem cell bank. The bank also continues
ImStem Biotechnology has successfully treated an animal model of multiple sclerosis (MS) using human embryonic stem cells (hESC) derived mesenchymal stem cells (MSCs), called hES-MSCs (…)
Now researchers from ImStem, in collaboration with University of Connecticut Health Center (UCHC) and Advanced Cell Technology, Inc.(OTCBB:ACTC), have developed a novel therapy to treat MS with hES-MSCs.
They found that hES-MSCs are more effective in treating animal model of MS than MSCs from bone marrow of adult human donors (BM-MSC). This work is published in the June 5th 2014 online edition of Stem Cell Reports, the official journal of International Society for Stem Cell
A notice for 8 million euros in funding for stem cell projects, a line of research that promises important results for ocular diseases, Parkinson’s, heart diseases, and the fight against tumors was announced by deputy health minister Ferruccio Fazio, who while speaking to the AGI press agency underlined “the importance of regenerative medicine, one of the great hopes for the future, as well as biotechnologies for new treatments altering molecular systems”.
The notification will expire on July 20 and is intended for universities, the National Research Council (CNR), and other private and public research groups. Three independent judges, one of